Speculation in the hallways of United Nations headquarters in Geneva was rampant in the days and hours leading up to this afternoon’s election of a new director general to lead the UN World Health Organization, but solid information about who will win was hard to come by. The outcome after a series votes is expected sometime tonight. Update! According to sources, the first round of voting is over. Results: Tedros 95, Nabarro 52, Nishtar 38. Second round update! Tedros 121, Nabarro 62. Third round underway. Continue reading ->
The 70th annual World Health Assembly (WHA), now underway in Geneva, is shaping up to be one of the most consequential in memory. With a record-setting nine-day, 76-item agenda, plus dozens of official and unofficial side events, delegates and WHO followers alike will be hard-pressed to keep up. But yesterday’s introductory briefing, hosted by the Global Health Centre at the Graduate Institute, provided an overview of the proceedings and a few pointers on where to look first. Four items, in particular, stand out. Continue reading ->
The 70th annual World Health Assembly kicked off today with the focus of thousands on the grand plenary hall in United Nations headquarters in Geneva. But in the surrounding rooms and buildings in and outside of the UN, a wide array of side events is taking place. IP-Watch's Global Health Policy News took a look at a selection of these events and found this year a stronger focus has emerged on the subject of health security and the new UN Sustainable Development Goals (SDGs). These are occurring alongside the usual disease-specific events and those on various sectors of humanity, the focus on access to medical products, and a variety of other current topics. Continue reading ->
Taiwan will not be allowed to participate in the World Health Assembly (WHA) this year as an observer, the WHA has decided on its opening day. Some hours earlier today, Taiwan’s minister of health gave a press conference to denounce the fact that the country has not been invited by the World Health Organization, and saying that Taiwan needs the WHO, and the WHO needs Taiwan. Continue reading ->
Group of 20 health ministers today finished their first joint table top exercise to simulate the outbreak of a new deadly viral pandemic in “Anycountry” and passed a seven-page final resolution on pandemic preparedness and antimicrobial resistance. Non-governmental experts and health organizations welcomed the first ever meeting of health ministers in the G20 format, but see a risk of framing the debate from a global North security perspective. And despite a call of urgency with regard to antimicrobial resistance, the G20 could not agree to include the de-linking of the cost of investment in R&D from the price of medical products. Continue reading ->
It appears not just unfair, but absurdly so. The US government paid for research that produced a patented drug, the patents were licensed exclusively to a Japanese firm, and that firm is now committing price discrimination against the US. Astellas Pharma is selling its anti-prostate cancer drug, Xtandi, for over $129,000 per year per patient in the United States – triple the price of the drug in Japan. Alas, this situation is not unusual. Many drugs that were financed by US taxpayers are sold in the US at exorbitant prices, but are much cheaper in other high-income industrialized nations. This differential price problem could be solved easily. However, the US government has consistently refused to exercise its march-in rights in order to lower drug prices. Continue reading ->